Skip to main content

BILL Holdings, Inc.

For the period ended Sep 30, 2026. Filed Nov 6, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 6, 2026

BILL$53.74-0.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows

Three Months Ended September 30,
20262025
Cash flows from operating activities:
Net income (loss)$60,253$(2,962)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Stock-based compensation40,72758,805
Amortization of intangible assets15,16515,165
Depreciation of property and equipment5,8093,839
Amortization of capitalized internal-use software costs and other paid in cash10,4754,507
Amortization of debt discount and issuance costs1,6251,610
Accretion of discount on investments in marketable debt securities(4,340)(7,464)
Accretion of discount on loans held for investment(7,678)(6,533)
Provision for expected credit losses on acquired card receivables and other financial assets10,33012,190
Provision for expected credit losses on loans held for investment4,2103,906
Non-cash operating lease expense2,1472,019
Impairment of operating lease right-of-use assets and property and equipment25,838—
Other94368
Changes in assets and liabilities:
Accounts receivable385273
Prepaid expenses and other current assets(1,195)5,403
Other assets(531)(1,378)
Accounts payable(2,600)(9,797)
Other accruals and current liabilities(62,262)20,826
Operating lease liabilities(2,548)(2,331)
Deferred revenue905(1,591)
Net cash provided by operating activities96,80996,855
Cash flows from investing activities:
Purchases of corporate and customer fund short-term investments(188,513)(372,347)
Proceeds from maturities and sales of corporate and customer fund short-term investments436,518328,254
Purchases of loans held for investment(296,102)(241,680)
Principal repayments of loans held for investment290,122244,471
Acquired card receivables, net(84,771)(52,826)
Purchases of property and equipment(80)(1,299)
Capitalization of internal-use software costs(13,836)(13,294)
Other(942)—
Net cash provided by (used in) investing activities142,396(108,721)
Three Months Ended September 30,
20262025
Cash flows from financing activities:
Customer fund deposits liability(216,428)(68,715)
Prepaid card deposits(5,223)16,764
Repurchase of common stock(312,163)(83,145)
Proceeds from line of credit borrowings—150,000
Proceeds from exercise of stock options1,028276
Tax withholdings related to net share settlements of equity awards(17,958)(14,080)
Net cash provided by (used in) financing activities(550,744)1,100
Effect of exchange rate changes on cash, cash equivalents, restricted cash and restricted cash equivalents875
Net decrease in cash, cash equivalents, restricted cash, and restricted cash equivalents(311,531)(10,691)
Cash, cash equivalents, restricted cash, and restricted cash equivalents, beginning of period3,765,2333,550,885
Cash, cash equivalents, restricted cash, and restricted cash equivalents, end of period$3,453,702$3,540,194
Reconciliation of cash, cash equivalents, restricted cash, and restricted cash equivalents within the condensed consolidated balance sheets to the amounts shown in the condensed consolidated statements of cash flows above:
Cash and cash equivalents$915,475$1,099,628
Restricted cash included in other current assets141,237111,842
Restricted cash included in other assets3,3044,885
Restricted cash and restricted cash equivalents included in funds held for customers2,393,6862,323,839
Total cash, cash equivalents, restricted cash, and restricted cash equivalents, end of period$3,453,702$3,540,194
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.